The API5 Knockout Jurkat Polyclonal Cells are a human T-lymphocyte population engineered via CRISPR/Cas9 to disrupt the endogenous API5 gene. This polyclonal knockout product comprises a heterogeneous pool of edited cells, enabling studies of API5 loss without clonal selection bias. It is designed for advanced research into apoptosis, chemoresistance, and T-cell signaling.
Jurkat cells are an immortalized human T-cell leukemia line derived from an acute lymphoblastic leukemia patient. They serve as a classic model for T-cell receptor signaling, activation-induced cell death, and leukemic transformation, providing a physiologically relevant backdrop for interrogating anti-apoptotic mechanisms.
API5 (Apoptosis Inhibitor 5) suppresses apoptosis by directly binding caspase-9 to prevent its activation and by interacting with Acinus to block DNA fragmentation. Upstream, API5 expression is induced by FGF-2 and EGF via FGFR/EGFR, ERK1/2, and E2F transcriptional activation. API5 also interacts with PRPF19, a spliceosomal component, potentially linking survival signaling to mRNA processing. This positions API5 as a key node in the apoptosis-inhibitory network, frequently exploited by cancer cells for chemoresistance.
In Jurkat T-cell leukemia, API5 helps sustain malignant survival by antagonizing both intrinsic and extrinsic apoptotic signals. CRISPR/Cas9-mediated disruption of API5 in this polyclonal population allows assessment of altered caspase cascades, apoptotic thresholds, and drug sensitivity. The model is valuable for dissecting FGF-2/PI3K/AKT-mediated survival and investigating chemoresistance mechanisms in T-cell malignancies.
These cells are suitable for Western blotting to assess caspase-9 cleavage, flow cytometry for Annexin V staining, drug sensitivity assays, co-immunoprecipitation of API5 complexes, and RNA-seq for transcriptomic changes. The polyclonal format supports population-level analyses and screening applications. For additional technical details or custom inquiries, please contact Ascent Research.
